We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Janssen, Bayer Must Face Third Bellwether In Xarelto MDL

Law360, New York (July 24, 2017, 8:49 PM EDT) -- A Louisiana federal judge on Friday refused to grant Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. a quick win in a patient’s suit accusing them of not warning about the possibility of dangerous internal bleeding associated with the blood thinner Xarelto, allowing the third bellwether trial in the multidistrict litigation to move forward. 

In the request for partial summary judgment that U.S. District Judge Eldon E. Fallon denied, Janssen and Bayer argued that they didn’t have the authority to change the drug’s label and that state claims brought by Dora Mingo were preempted by federal law....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!



Kirkland & Ellis LLP has redefined what it means to be the biggest of BigLaw — weighing in at 2,116 attorneys by year end 2018 and becoming the first firm since Law360 began tracking law firm head counts to top 2,000 U.S.-based attorneys.



Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


Louisiana Eastern

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability


Subscribers Only

Date Filed

December 12, 2014

Law Firms


Government Agencies

Judge Analytics